

CORRECTION



Correction: Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells


Maria Eugenia Balañá, Leticia Labriola, Mariana Salatino, Federico Movsichoff, Giselle Peters, Eduardo H. Charreau and Patricia V. Elizalde

© The Author(s), under exclusive licence to Springer Nature Limited 2023

Oncogene (2023) 42:3087; <https://doi.org/10.1038/s41388-023-02821-4>

Correction to: *Oncogene* <https://doi.org/10.1038/sj.onc.1204050>, published online 17 January 2001

Following publication of this article it was noted that a Western blot (WB) in Figure 4 was inadvertently reproduced from Figure 6, panel D, of an article [1] published by the authors in the journal in 1999. The authors have provided the correct raw data corresponding to Figure 4 and the corrected figure (shown below).



The authors highlight that the findings shown in Figure 4 (C4HD cells, upper panel), which contain the inadvertent mistake, were also shown –even in a more specific manner– in Figure 5B ErbB-2 of the same article. In the experiment which results were shown in Figure 5B ErbB-2, C4HD cells cultured in MPA 10 nM were treated with ErbB-2 ASODNs or SODNs. In order to control for the levels of IGF-R protein expression in cells transfected with ErbB-2 ASODNs or SODNs, one mg protein from cell lysates was immunoprecipitated with an IGF-IR alpha chain antibody (Santa Cruz 2C8), and immunoblotted with an IGF-IR alpha chain antibody (Santa Cruz N-20) (middle panel). Membranes shown in the middle panel were then stripped and blotted with an IGF-IR beta chain antibody (lower panel). As can be seen, the middle and lower panels of Figure 5B ErbB-2, clearly show

that silencing ErbB-2 expression in C4HD cells by using ASODNs does not affect neither IGF-IR alpha nor IGF-IR beta chains protein levels.

The authors apologize for any inconvenience caused and confirm the error in assembly does not affect the conclusions of the article.

REFERENCE

1. Balañá M, Lupu R, Labriola L, et al. Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas. *Oncogene*. 1999;18:6370–9. <https://doi.org/10.1038/sj.onc.1203028>.